[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DOP2020000100A - Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 - Google Patents

Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Info

Publication number
DOP2020000100A
DOP2020000100A DO2020000100A DO2020000100A DOP2020000100A DO P2020000100 A DOP2020000100 A DO P2020000100A DO 2020000100 A DO2020000100 A DO 2020000100A DO 2020000100 A DO2020000100 A DO 2020000100A DO P2020000100 A DOP2020000100 A DO P2020000100A
Authority
DO
Dominican Republic
Prior art keywords
compounds
pirrolo
inhibitors
pyrimidine derivatives
novel pyrazolo
Prior art date
Application number
DO2020000100A
Other languages
English (en)
Inventor
Koppitz Marcus
Pook Elisabeth
Neuhaus Roland
Martin Fischer Oliver
Rotgeri Andrea
Bräuer Nico
Siebeneicher Holger
Nagel Jens
James Davenport Adam
Lindsay Carr James
James Townsend Robert
Connelly Ursinyova Nina
Anne Parrott Shelley
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of DOP2020000100A publication Critical patent/DOP2020000100A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención cubre compuestos de pirazolo-pirrolo-pirimidin-diona sustituidos (PPPD) de la fórmula general (I): (I) en la cual R1, R2 y R3 son como se los define en esta memoria, métodos de preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos, y el uso de dichos compuestos para la fabricación de composiciones farmacéuticas para el tratamiento o la profilaxis de enfermedades, en particular de enfermedades neurogénicas, como agente único en combinación con otros principios activos.
DO2020000100A 2017-10-27 2020-06-01 Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 DOP2020000100A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17198769 2017-10-27
PCT/EP2018/078567 WO2019081343A1 (en) 2017-10-27 2018-10-18 NOVEL PYRAZOLO-PYRROLO-PYRIMIDINE-DIONE DERIVATIVES AS P2X3 INHIBITORS

Publications (1)

Publication Number Publication Date
DOP2020000100A true DOP2020000100A (es) 2020-09-15

Family

ID=60190695

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2020000100A DOP2020000100A (es) 2017-10-27 2020-06-01 Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3

Country Status (25)

Country Link
US (1) US11319324B2 (es)
EP (1) EP3700907B1 (es)
JP (1) JP7250011B2 (es)
KR (1) KR20200078567A (es)
CN (1) CN111527090B (es)
AU (1) AU2018354777A1 (es)
BR (1) BR112020008122B1 (es)
CA (1) CA3080249A1 (es)
CL (1) CL2020001107A1 (es)
CO (1) CO2020005065A2 (es)
CR (1) CR20200174A (es)
CU (1) CU20200038A7 (es)
DK (1) DK3700907T3 (es)
DO (1) DOP2020000100A (es)
EA (1) EA202091003A1 (es)
EC (1) ECSP20023626A (es)
ES (1) ES2914377T3 (es)
IL (1) IL274036A (es)
JO (1) JOP20200100A1 (es)
MA (1) MA50439A (es)
MX (1) MX2020004981A (es)
NI (1) NI202000031A (es)
PH (1) PH12020550494A1 (es)
SG (1) SG11202003662XA (es)
WO (1) WO2019081343A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112778311B (zh) * 2019-11-01 2024-06-04 上海翰森生物医药科技有限公司 含氮并环类衍生物抑制剂、其制备方法和应用
CA3160875A1 (en) * 2019-12-10 2021-06-17 Hualing XIAO Pyrazole-containing polycyclic derivative inhibitor, preparation method therefor and application thereof
WO2022175514A1 (en) * 2021-02-22 2022-08-25 Bayer Aktiengesellschaft N-(pyridin-2-yl)-acetamides as p2x3 inhibitors
US20240351992A1 (en) * 2021-08-17 2024-10-24 Glaxosmithkline Intellectual Property (No.3) Limited Preparation of p2x3 antagonist

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03506029A (ja) * 1988-07-21 1991-12-26 ジ・アップジョン・カンパニー ピラゾロ―ピロロ―ピリミジン―ジオン類
AU707530B2 (en) * 1995-09-28 1999-07-15 Otsuka Pharmaceutical Factory, Inc. Analgesic composition
KR20020050257A (ko) 1999-11-05 2002-06-26 로즈 암스트롱, 크리스틴 에이. 트러트웨인 Ａｃａｔ 저해제에 의한 플라크 파열의 방지
TWI423977B (zh) 2006-06-23 2014-01-21 Incyte Corp 作為ｈｍ７４ａ同效劑之嘌呤酮衍生物（一）
US20090099195A1 (en) 2007-05-08 2009-04-16 Astrazeneca Ab Therapeutic Compounds 570
EP2675440B1 (en) 2011-02-14 2020-03-25 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
CN103874700B (zh) * 2011-08-12 2018-03-30 霍夫曼-拉罗奇有限公司 吡唑并[3,4‑c]吡啶化合物和使用方法
WO2013182519A1 (en) * 2012-06-04 2013-12-12 Universitaet Basel Combination of lysosomotropic or autophagy modulating agents and a gsk-3 inhibitor for treatment of cancer
WO2013185124A1 (en) 2012-06-08 2013-12-12 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
WO2014113429A2 (en) * 2013-01-16 2014-07-24 Signal Pharmaceuticals, Llc Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
EP3700907A1 (en) 2020-09-02
WO2019081343A1 (en) 2019-05-02
EP3700907B1 (en) 2022-03-09
US20210317128A1 (en) 2021-10-14
BR112020008122B1 (pt) 2022-11-01
ES2914377T3 (es) 2022-06-10
JP7250011B2 (ja) 2023-03-31
NI202000031A (es) 2020-08-28
CU20200038A7 (es) 2021-03-11
KR20200078567A (ko) 2020-07-01
CL2020001107A1 (es) 2020-10-23
JP2021500380A (ja) 2021-01-07
EA202091003A1 (ru) 2020-09-11
DK3700907T3 (da) 2022-05-30
CO2020005065A2 (es) 2020-05-29
SG11202003662XA (en) 2020-05-28
US11319324B2 (en) 2022-05-03
BR112020008122A2 (pt) 2020-11-03
CA3080249A1 (en) 2019-05-02
CR20200174A (es) 2020-06-26
AU2018354777A1 (en) 2020-04-16
MA50439A (fr) 2021-05-19
CN111527090A (zh) 2020-08-11
PH12020550494A1 (en) 2021-01-11
MX2020004981A (es) 2020-08-24
ECSP20023626A (es) 2020-06-30
CN111527090B (zh) 2023-05-26
JOP20200100A1 (ar) 2020-05-06
IL274036A (en) 2020-06-30

Similar Documents

Publication Publication Date Title
DOP2019000117A (es) Nuevos derivados de quinolina
DOP2020000023A (es) Nuevos derivados de quinolina
CL2017002650A1 (es) Compuestos novedosos
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
DOP2018000268A (es) Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos
DOP2016000208A (es) Benzimidazol-2-aminas como inhibidores de midh1
DOP2017000261A (es) Derivados de ciclohexano sustituido con amido
CR20170384A (es) Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2019014484A2 (es) Nuevos derivados de azaquinolina
DOP2020000100A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2019011877A2 (es) Nuevos derivados de pirazol bicíclicos
CO2020001242A2 (es) Dihidrooxadiazinonas
DOP2016000253A (es) Nuevos compuestos
CL2020002891A1 (es) Nuevos derivados de quinolina
UY37971A (es) Derivados de indol macrocíclicos sustituidos
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
UY37250A (es) Derivados macrocíclicos de indol
UY37973A (es) Derivados de indol macrocíclicos
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
DOP2016000251A (es) Inhibidores de las vías de señalización de wnt
UY37444A (es) Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y su uso
UY37032A (es) Compuestos de heteroarilbenzimidazol